Meningococcal Chemoprophylaxis: Protecting Close Contacts

1. Why Chemoprophylaxis Is Needed
2. Who Is a Close Contact?
3. Rifampicin — the Traditional First-Line
4. Ciprofloxacin — the Single-Dose Alternative
5. Ceftriaxone IM — the Injectable Option
6. Timing of Prophylaxis — the Earlier the Better
7. Healthcare Workers — Who Needs Prophylaxis?
8. Clearing the Index Case's Own Carriage
9. Antibiotic Resistance in N. meningitidis
10. Key Research Papers
11. Connections
12. Featured Videos

Why Chemoprophylaxis Is Needed

When someone develops invasive meningococcal disease, their close contacts face a dramatically elevated risk of becoming ill themselves. Studies have found that household contacts of meningococcal cases have approximately 500 to 800 times the risk of the general population in the days immediately following the index case's illness. This is not a small increase — this is an emergency that justifies urgent action.

The reason close contacts are at such high risk is straightforward. Neisseria meningitidis lives in the back of the throat in roughly 10% of the general population at any given time without causing disease. But when someone develops invasive meningococcal disease, the particular strain causing their illness has already proven itself capable of crossing from the mucosa into the bloodstream. Close contacts who share the same bacterium in their throats — acquired through the same close respiratory contact that transmitted it to the index case — face the risk of the same invasive progression.

Chemoprophylaxis — giving antibiotics to close contacts — aims to eradicate the organism from the nasopharynx before it can cause invasive disease. By clearing carriage in everyone exposed, the chain of transmission is broken and secondary cases are prevented. This is why public health authorities move quickly to identify and contact every close contact as soon as a case is confirmed.

Back to Table of Contents

Who Is a Close Contact?

The definition of "close contact" for chemoprophylaxis purposes is important because giving antibiotics to everyone who was in the same building or attended the same class wastes resources and creates unnecessary antibiotic pressure. The criteria are specific:

• Household members: Anyone living in the same house as the index case is a close contact, regardless of the exact nature of their relationship. This includes family members, housemates, and anyone sleeping regularly in the same home.
• Kissing contacts: Sexual or intimate partners who have shared saliva with the index case in the 7–10 days before symptoms developed.
• People who shared eating or drinking utensils: Sharing a bottle, cup, spoon, or food requiring direct mouth contact may transfer the organism.
• People who smoked the same cigarette: Sharing a cigarette (or similar) transfers oral secretions containing the bacterium.
• People who performed mouth-to-mouth resuscitation without barrier protection: Direct exposure to respiratory secretions in a resuscitation attempt creates significant risk.
• Bunkmates in military, dormitory, or boarding school settings: People sleeping in the same bay or room with ongoing close contact.

Crucially, many exposures do NOT qualify as close contact:

• Being in the same classroom, office, or social gathering as the index case
• Sitting near the index case on public transport
• Being at the same party without sustained intimate contact
• Healthcare workers who provided routine care (see dedicated section below)

The distinction matters because public health resources are finite, and broad antibiotic use in low-risk contacts drives resistance without preventing secondary cases.

Back to Table of Contents

Rifampicin — the Traditional First-Line

Rifampicin (rifampin in the US) has been used for meningococcal chemoprophylaxis since the 1960s and remains a first-line option in many guidelines. It works by inhibiting bacterial RNA polymerase, blocking bacterial transcription and killing the organism in the nasopharynx.

Standard dosing:

• Adults and children over 12 years: 600mg twice daily for 2 days (4 doses total)
• Children 1 month to 12 years: 10mg/kg twice daily for 2 days (maximum 600mg per dose)
• Infants under 1 month: 5mg/kg twice daily for 2 days

Rifampicin achieves over 90% eradication of nasopharyngeal carriage, which is excellent. However, several practical points must be communicated to contacts receiving it:

• Orange discoloration: Rifampicin turns urine, tears, saliva, and sweat an orange-red color. This is harmless but alarming if unexpected. Contact lens wearers should avoid wearing contacts during the treatment course and for a few days after, as the drug can permanently stain soft lenses.
• Oral contraceptive interaction: Rifampicin is a potent inducer of cytochrome P450 enzymes and significantly reduces the blood levels of hormonal contraceptives. Women taking the oral contraceptive pill should use additional contraceptive protection during the treatment course and for at least 7 days after completing rifampicin.
• Hepatotoxicity: Rare but possible, particularly with pre-existing liver disease. At the short 2-day course used for prophylaxis, this risk is very low.
• Resistance: Rifampicin-resistant strains of N. meningitidis have been documented and have occasionally caused secondary cases in contacts who received rifampicin prophylaxis. This is one reason why alternatives are increasingly preferred.

Back to Table of Contents

Ciprofloxacin — the Single-Dose Alternative

Ciprofloxacin given as a single oral dose has become the preferred chemoprophylaxis option in many countries because of its simplicity and high efficacy. A single 500mg dose in adults achieves over 90% eradication of nasopharyngeal carriage and has no significant effect on oral contraceptives — a major practical advantage over rifampicin.

Ciprofloxacin is particularly preferred in:

• Pregnant women: Rifampicin has limited safety data in pregnancy. Ciprofloxacin, while a fluoroquinolone (which have generally been avoided in pregnancy due to theoretical cartilage concerns), has a better-established safety record in short-course use and is considered acceptable by most authorities for this indication.
• Women taking oral contraceptives: Avoids the enzyme-induction interaction.
• Settings where compliance is a concern: A single observed dose guarantees treatment completion in a way that a 2-day multi-dose course cannot.
• Healthcare settings: Easier to administer a single dose to healthcare contacts than to coordinate a 2-day course.

Ciprofloxacin is NOT recommended as routine prophylaxis in children under 18 years because fluoroquinolones have been associated with cartilage damage in juvenile animal studies, although this risk appears to be theoretical rather than clinically proven in humans. Most guidelines use rifampicin or ceftriaxone for children.

Importantly, ciprofloxacin resistance in N. meningitidis has been reported, with cases of prophylaxis failure due to resistant organisms documented in several countries. This needs ongoing surveillance — if ciprofloxacin-resistant strains become established in a community, rifampicin or ceftriaxone would need to replace ciprofloxacin as the local first-line choice.

Back to Table of Contents

Ceftriaxone IM — the Injectable Option

Ceftriaxone given as a single intramuscular injection is highly effective for meningococcal chemoprophylaxis and is the preferred option in certain situations:

• Pregnant women in some countries: Where concerns about ciprofloxacin in pregnancy remain, ceftriaxone IM 250mg is the preferred alternative.
• Patients already hospitalised: If a household contact is in hospital for another reason when the index case is identified, IV or IM ceftriaxone can be administered easily.
• Children: Ceftriaxone IM 125mg (under 15 years) or 250mg (15 years and over) is effective and avoids the oral compliance issues that can affect rifampicin in young children.

Standard dosing for ceftriaxone prophylaxis:

• Adults (15 years and over): 250mg IM single dose
• Children under 15 years: 125mg IM single dose
• Pregnant women: 250mg IM single dose (across all ages)

The requirement for an injection is the main practical limitation, as it requires either a healthcare setting or a trained provider. For community-based contact tracing, oral options (rifampicin or ciprofloxacin) are usually more logistically feasible.

Ceftriaxone has the additional advantage of being the treatment drug for systemic meningococcal disease, so it also eradicates any blood-borne bacteria in contacts who may have incipient bacteremia — not just nasopharyngeal carriage.

Back to Table of Contents

Timing of Prophylaxis — the Earlier the Better

The window for effective chemoprophylaxis is narrow. Secondary cases of meningococcal disease most commonly occur within 7–10 days of the primary case. Prophylaxis given within 24 hours of identifying the index case has the best chance of interrupting transmission before another contact develops invasive disease.

The typical sequence of events:

1. Index case diagnosed with meningococcal disease and notified to public health authorities (legally required in most countries).
2. Public health team contacts the treating clinician to gather information about close contacts.
3. All identified close contacts are contacted — typically by telephone or in person — within 24 hours of case notification.
4. Chemoprophylaxis is arranged for close contacts, ideally within 24 hours of the index case diagnosis and definitely within 7 days.
5. Vaccination of contacts may also be offered (MenACWY if the serogroup is A, C, W, or Y; MenB if serogroup B) to provide longer-term protection beyond the antibiotic window.

Prophylaxis is still considered worthwhile up to 14 days after the last exposure to the index case. Beyond 14 days, the risk of secondary cases drops substantially — though not to zero — and the calculus shifts toward offering vaccination rather than antibiotics. If chemoprophylaxis is delayed beyond 7–14 days, it is generally given anyway in high-risk settings (household contacts, institutional settings with multiple cases).

Back to Table of Contents

Healthcare Workers — Who Needs Prophylaxis?

Fear of meningococcal disease among healthcare workers is understandable — caring for a patient with this terrifying illness creates anxiety about personal risk. However, the vast majority of healthcare contacts with meningococcal patients do not require chemoprophylaxis, and giving unnecessary antibiotics to hundreds of staff after each case is both wasteful and promotes antibiotic resistance.

Chemoprophylaxis IS indicated for healthcare workers who had:

• Mouth-to-mouth resuscitation without barrier protection: Direct transfer of large volumes of respiratory secretions constitutes mucosal exposure.
• Intubation without a face mask: The close proximity of the intubator to the patient's airways during laryngoscopy, combined with the patient's respiratory secretions, constitutes relevant exposure.
• Airway suctioning without a mask: Generating aerosols directly from the patient's respiratory tract with exposed mucous membranes.

Chemoprophylaxis is NOT indicated for healthcare workers who:

• Took blood, inserted IV cannulas, gave medications, or performed routine nursing care — even without gloves
• Were in the same room during examination or routine care with standard precautions
• Were on the same ward but not directly involved in airway management or resuscitation
• Spoke briefly with the patient at normal conversational distance

The key distinction is direct mucosal exposure to respiratory secretions, not simply being near the patient. N. meningitidis does not float through the air like measles or tuberculosis — it is spread through respiratory droplets that require close face-to-face contact or direct secretion exchange. Normal hospital activity does not meet this threshold.

Back to Table of Contents

Clearing the Index Case's Own Carriage

A fact that surprises many people: the index case — the patient who was hospitalised with meningococcal disease — may need a prophylaxis course themselves before going home. This is because the antibiotics used to treat systemic disease do not all reliably eradicate nasopharyngeal carriage.

• Penicillin and ampicillin: Do NOT reliably clear nasopharyngeal carriage of N. meningitidis, despite being effective at treating blood and CSF infection. A patient treated with penicillin who goes home without additional prophylaxis may still carry live bacteria in their throat and could reintroduce the organism to household members who completed prophylaxis based on the index case's illness.
• Ceftriaxone: Does reliably clear nasopharyngeal carriage. A patient who received IV ceftriaxone as their primary treatment does not need additional prophylaxis before discharge.
• Recommendation: If the index case was treated with penicillin or ampicillin (or any agent that does not reliably clear carriage), they should receive a prophylaxis course (rifampicin 2 days, single-dose ciprofloxacin, or single-dose ceftriaxone IM) before discharge.

Clinicians should document which antibiotic the index case received and whether prophylaxis was given, so that the public health team can advise household contacts correctly.

Back to Table of Contents

Antibiotic Resistance in N. meningitidis

Unlike many other bacterial pathogens, Neisseria meningitidis has remained largely susceptible to the antibiotics used to treat and prevent meningococcal disease. However, resistance is not zero, and surveillance is important.

Key resistance patterns:

• Rifampicin resistance: Has been documented in N. meningitidis following chemoprophylaxis use. Rifampicin-resistant secondary cases have been reported, where a contact took rifampicin but still developed disease with a rifampicin-resistant organism. The mechanism is mutation in the rpoB gene (the same gene affected in Mycobacterium tuberculosis). Resistance rates remain low overall but are the primary reason ciprofloxacin has largely replaced rifampicin as the preferred prophylactic agent in many countries.
• Penicillin intermediate resistance: Now found in 15–25% of clinical isolates in some European countries due to alterations in penicillin-binding protein 2 (PBP2). These strains are not fully resistant but have reduced susceptibility, meaning standard penicillin dosing may not achieve adequate CSF concentrations. Ceftriaxone, which is not affected by these PBP2 alterations, remains fully effective against these isolates.
• Full penicillin resistance: Rare — only sporadic case reports from a small number of countries. Not considered a routine clinical concern in most settings but warrants susceptibility testing in treatment failures.
• Fluoroquinolone resistance: Emerging, particularly in Asia. Several clusters of ciprofloxacin-resistant meningococcal disease have been reported in China and India. Globally, fluoroquinolone resistance remains rare but is being monitored. If local epidemiology indicates significant fluoroquinolone resistance, rifampicin or ceftriaxone should replace ciprofloxacin as the local prophylaxis of choice.
• Ceftriaxone resistance: Exceedingly rare — no confirmed treatment failures attributable to ceftriaxone resistance in N. meningitidis have been reported in the literature. This makes ceftriaxone the most reliable drug for both treatment and prophylaxis, at the cost of requiring injection.

Surveillance of antimicrobial susceptibility in meningococcal isolates — carried out by reference laboratories in most high-income countries — is essential to detecting emerging resistance patterns before they affect public health practice. Public health agencies should be notified of any suspected prophylaxis failures.

Back to Table of Contents

Key Research Papers

1. Rosenstein NE, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388. PMID 11333996
2. Cohn AC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2013;62(RR-2):1–28. PMID 23445929
3. Riedo FX, et al. A school outbreak of meningococcal disease. J Infect Dis. 1995;172(3):788–795. PMID 7658073
4. Zalmanovici Trestioreanu A, et al. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2011;(8):CD004785. PMID 21833946
5. Jackson LA, et al. Emergence of Neisseria meningitidis with decreased susceptibility to rifampin. Antimicrob Agents Chemother. 1994;38(10):2364–2367. PMID 7840571
6. Plourd MR, et al. Single dose ciprofloxacin for eradication of pharyngeal carriage of Neisseria meningitidis. Epidemiol Infect. 2002;129(2):277–281. PMID 12403104
7. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–2210. PMID 17604802
8. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467–492. PMID 20610819
9. Wang JF, et al. Rates of switching between Neisseria meningitidis serogroups with emphasis on quinolone resistance. Emerg Infect Dis. 2008;14(2):353–355. PMID 18258120
10. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53(Pt 9):821–832. PMID 15314188

Back to Table of Contents

Connections

• Treatment & Prevention Overview
• Antibiotic Treatment: Ceftriaxone and Dexamethasone
• Meningococcal Vaccines
• Symptoms & Diagnosis
• Neisseria Meningitidis Overview
• All Bacteria

Back to Table of Contents

Featured Videos